Sarepta Therapeutics Stock Soars on FDA Approval
SRPT Sarepta Therapeutics $160.72 +37.22 (+30.14%) (As of 05:50 PM ET) 52-Week Range $55.25 ▼ $173.25 P/E Ratio 1,461.09 Price Target $177.65 Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics’ stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular…